“Personalized” battle against GI cancers: ASCO GI 2024 highlights
Personalized medicine is revolutionizing the field of oncology, and gastrointestinal (GI) cancers are at the forefront. While immunotherapy has made a transformational impact in many areas, it hasn’t seen the same success in GI cancers. This has led to rising recognition of cancer heterogeneity and highlighting the need for personalization for therapeutic benefit in subpopulations.
The key highlights at ASCO GI 2024 resonated with the theme of ‘Taking Personalized Care to the Next Level’ and provided a glimpse into the future of personalized medicine for GI cancers. Discover the post-conference takeaways from Inizio Advisory here.
Here’s how we help to shape the future of oncology treatments.
Jump to a slide with the slide dots.
3 Pharmaceutical Data Strategy & Market Research Tactics to Make Confident Commercial Decisions
Pharma leaders harness data & AI for insights, but confidence requires a strong foundation. Learn why pausing can drive better decisions.
Read moreSupercharge Strategy with Targeted Innovation
Unlock the potential of data and AI with InizioNavigator.ai, combining pharma expertise and advanced tools to solve key challenges and innovation.
Read morePatient-centricity in oncology and why it’s more important than ever
While significant progress has been made in focusing on patient needs, our experts emphasize that much still needs to be done.
Read more